Technical Articles

This article reviews CD40 agonism in immuno-oncology research: licensing dendritic cells, reversing the cold tumor phenotype, the safety trade-offs of systemic agonism and what standardized CD40 reagents contribute to preclinical workflows.

Natural killer cells are currently at the forefront of many immunotherapy strategies, and new methods are being developed to fully harness the anti-tumor potential of NK cells. NK cells play a critical role in tumor immunity and are increasingly becoming a cutting-edge area in immunotherapy strategies.